Following several recalls for blood pressure medication over the last few months because of a cancer-causing impurity, Macleods Pharmaceuticals Limited has issued a recall for 32 lots of Losartan Potassium USP tablets and Losartan Potassium/Hydrochlorothiazide combination tablets for an impurity that could cause cancer.

The recalled blood pressure medication has trace amounts of an unexpected impurity, N-Nitroso-N-methyl-4-aminobutyric acid (NMBA), above the limits allowed by the U.S. Food and Drug Administration (FDA). NMBA is a known carcinogen that could lead to cancer.

Both Losartan Potassium and Losartan Potassium/Hydrochlorothiazide combination tablets are used to treat hypertension and hypertensive patients with left ventricular hypertrophy.

The recalled blood pressure medication is packaged in bottles and can be identified by checking the product name, manufacturer details, and batch or lot number. A full list of recalled medications can be viewed here. Labels of the recalled blood pressure medication can be viewed here.

Patients that have been prescribed the recalled blood pressure medication should continue to take the medication and contact their pharmacist, physician, or medical provider for an alternative treatment. The risk of stopping the recalled medication without alternative treatment is greater than continuing to take the medication, the company said.

The company has not received any reports of adverse effects due to the recall. Patients that have issues from the recalled medication should contact their healthcare provider.

Medical questions about the recall or to report adverse effects from the recalled medication can be directed to MacLeods Pharmaceuticals Limited at 1-855-926-3384 from 8 a.m. to 5 p.m. ET.

General questions about the return of the product can be directed to Qualanex at 1-888-280-2046, Monday through Friday from 7 a.m. to 4 p.m. CST or by emailing recall@qualanex.

Blood Pressure Med Recall 87 lots Camber Pharmaceuticals has recalled 87 lots of blood pressure medication for a possible cancer-causing impurity. The Omron HeartGuide wearable device is displayed during a press event for CES 2019 at the Mandalay Bay Convention Center on January 6, 2019 in Las Vegas, Nevada. The just released smartwatch is able to monitor blood pressure and sells for USD 499. CES, the world's largest annual consumer technology trade show, runs from January 8-11 and features about 4,500 exhibitors showing off their latest products and services to more than 180,000 attendees. Photo: Getty Images/David Becker